PPMD Community

All Blog Posts Tagged 'Staff' (574)


Staff
Every Single Family

In the 20+ years PPMD has been around, the average lifespan of people with Duchenne has increased. This incredible leap is not because of any drug interventions or treatments because as we all know, to date there are no approved therapies. Rather this is because of the push from PPMD to advance care over the last two decades.

PPMD strives to ensure that every single person with Duchenne receives optimal care. …

Continue

Added by PPMD on July 28, 2016 at 2:18pm — No Comments


Staff
PTC Therapeutics Provides Regulatory Update on Translarna™

PTC recently participated in discussions with FDA to discuss the Refuse to File (RTF) letter issued on February 22, 2016 with respect to the company's New Drug Application (NDA) for Translarna for the treatment of Duchenne. Today PTC…

Continue

Added by Pat Furlong on July 25, 2016 at 12:00pm — No Comments


Staff
Every Single Therapy

At the heart of PPMD’s mission lies our unwavering commitment to seek out, fund, and nurture the most promising Duchenne research – more specifically, therapies with the potential to help every single diagnosis.

Your sustaining gift to PPMD will help us continue to take a…

Continue

Added by PPMD on July 21, 2016 at 11:25am — No Comments


Staff
Every Single Connection

For more than two decades, PPMD has helped to change the landscape of Duchenne in every area – research, care, advocacy, and awareness. You have made this possible. Every single person that supports PPMD gives us the resources we need to have the greatest impact, to attack Duchenne from every angle.

Today, we are asking you to consider making a monthly,…

Continue

Added by PPMD on July 19, 2016 at 11:22am — No Comments


Staff
Thank you to our 2016 Connect Conference Resource Fair Providers!

The 2016 Connect Conference again provided a forum for families to interact with a variety of resource providers. We thank our resource fair sponsors for working with us to make every single resource known to our community!…

Continue

Added by PPMD on July 14, 2016 at 1:36pm — No Comments


Staff
Santhera Updates on U.S. Regulatory Filing for Raxone® (idebenone) in Duchenne

PPMD is deeply disappointed with the FDA’s conclusion regarding Santhera's proposed subpart H (Accelerated Approval) for Raxone (idebenone). Because individuals in the study were not taking steroids, FDA has recommended Santhera complete the SIDEROS study on individuals using…

Continue

Added by PPMD on July 14, 2016 at 9:00am — 1 Comment


Staff
PTC Initiates Phase 2 Clinical Trial of Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy in Pediatric Patients Between the Ages of Two and Five Years

PTC Therapeutics has announced that they have initiated a Phase 2 clinical trial of Translarna™ (ataluren) for children 2 to 5 years old. Details of site locations, etc. are on clinicaltrials.gov.  Below is the announcement…

Continue

Added by PPMD on July 5, 2016 at 10:30am — No Comments


Staff
PPMD Awards The Ohio State University Grant to Support Cardiomyopathy Therapy for Duchenne

Parent Project Muscular Dystrophy (PPMD) announced today plans to award Dr. Denis Guttridge of The Ohio State University with a $48,000 grant for his work in cardiac issues in Duchenne. Duchenne affects muscles, and since the heart is a muscle too,…

Continue

Added by PPMD on June 22, 2016 at 10:30am — No Comments


Staff
BioMarin Update for the Duchenne Community



BioMarin is providing a further update to the Duchenne Community in light of recent announcements of withdrawal of the EMA marketing application and discontinuation of clinical and regulatory development of drisapersen (BMN 051) and follow-on products BMN 044, BMN 045 and BMN 053. 

Is there any Update…

Continue

Added by PPMD on June 20, 2016 at 9:30am — No Comments

Genetic Testing for Duchenne & Becker: When Is Re-Testing Needed?

Genetic counselors, whether they are part of PPMD's DuchenneConnect team or part of your local care team, are an excellent resource to consider when you have questions about genetic test results for Duchenne and Becker muscular…

Continue

Added by Lauren Bogue on June 16, 2016 at 12:00pm — 1 Comment


Staff
Understanding Gene Therapy & CRISPR/Cas9

You’ve seen the headlines and heard the name, now find out more about the latest in gene therapy, CRISPR/Cas9, and what these technologies could mean for Duchenne during three different opportunities that promise to provide an in-depth analysis:



  • Gene Therapy and…
Continue

Added by Abby Bronson on June 16, 2016 at 11:04am — No Comments


Staff
PPMD Responds to Threat to Lose DOD Funding

Our Duchenne community’s life-saving research efforts are funded through a number of public and private sources. Beginning in FY 2011, the federal funding to Duchenne began to include the Congressionally Directed Medical…

Continue

Added by Annie Kennedy on June 16, 2016 at 11:00am — No Comments


Staff
Getting Results: Success from your Advocacy efforts in February!

Thanks to your advocacy, this week we learned that all of the Duchenne priorities we advocated for this year with Members of Congress are one step closer to being included in next year’s budget.

 

Whether you traveled to DC for face-to-face meetings with members, or advocated from…

Continue

Added by Ryan Fischer on June 10, 2016 at 12:00pm — No Comments


Staff
PPMD Awards University of Washington Grant to Support Technology to Help Optimize Gene Therapy

The promise of gene therapy continues to build momentum, in Duchenne and also in other conditions. Much has been learned about the immunological and delivery challenges of the approach since gene therapy’s early attempts in the 1990s.

In Duchenne, some of the early work in gene therapy ended with immune system reactions to the new dystrophin that was expressed by the transfected gene. But this was not…

Continue

Added by Abby Bronson on June 9, 2016 at 12:00pm — No Comments


Staff
PPMD & BIO Release New Report on the Development of Patient Preference Studies

Today, the Biotechnology Innovation Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) released a new report, “Key Considerations for Developing and Integrating Patient…

Continue

Added by PPMD on June 8, 2016 at 12:00pm — No Comments


Staff
National 21st Century Cures Act/ Senate Cures Day of Advocacy - TODAY!

As you know, PPMD has been helping to lead national advocacy efforts around the 21st Century Cures/ Senate Innovation legislation for more than two years and we now have a very short window of opportunity in which the…

Continue

Added by Annie Kennedy on June 7, 2016 at 1:00pm — No Comments


Staff
New Data from Santhera’s Phase III Trial (DELOS) in Duchenne Published in Neuromuscular Disorders

Santhera Pharmaceuticals announced today that additional data from the pivotal phase III trial (DELOS) were published online as an article in press in…

Continue

Added by PPMD on June 1, 2016 at 12:00pm — 1 Comment


Staff
BioMarin Discontinues Clinical Development of Drisapersen



Today is June 1 and I know many of us feel like 2016 has beat up this community already. With every small victory, we face another major setback.

 

As you have heard by now,…

Continue

Added by Pat Furlong on June 1, 2016 at 9:57am — 2 Comments


Staff
PPMD’s #EverySingleOne Tour: Salt Lake City

With a successful ESO tour stop in Baltimore under our belts, PPMD visited Salt Lake City this past weekend! There’s a special sense of…

Continue

Added by Kathi Kinnett on May 26, 2016 at 3:00pm — No Comments


Staff
Sarepta Announces FDA Will Not Complete the Review of the Eteplirsen NDA By The PDUFA Date

The FDA has notified Sarepta that they are continuing their review of eteplirsen and will not be able to complete…

Continue

Added by PPMD on May 25, 2016 at 12:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

© 2016   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service